Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the five analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $13.75.

Several equities research analysts have weighed in on TBPH shares. TD Cowen decreased their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th.

Theravance Biopharma Stock Up 8.6 %

TBPH stock opened at $9.68 on Thursday. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71. The firm has a market cap of $473.56 million, a price-to-earnings ratio of -9.58 and a beta of 0.25. The company’s fifty day simple moving average is $8.32 and its 200 day simple moving average is $8.68.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The company had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same period last year, the firm posted ($0.17) earnings per share. Research analysts expect that Theravance Biopharma will post -1.04 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Quantbot Technologies LP purchased a new position in Theravance Biopharma during the third quarter worth about $60,000. China Universal Asset Management Co. Ltd. boosted its stake in Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,696 shares during the last quarter. Ballentine Partners LLC purchased a new position in Theravance Biopharma in the third quarter valued at about $104,000. Hsbc Holdings PLC purchased a new position in Theravance Biopharma in the second quarter valued at about $108,000. Finally, XTX Topco Ltd purchased a new position in Theravance Biopharma in the second quarter valued at about $129,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.